MRD in AML: does it already guide therapy decision-making?

Area of Science:

• Hematology
• Oncology
• Clinical Pathology

Background:

• Morphological complete remission (CR) is a standard endpoint in acute myeloid leukemia (AML) treatment.
• Residual disease post-therapy can indicate resistance mechanisms and impact patient outcomes.
• Minimal residual disease (MRD) detection offers a more sensitive measure of treatment response.

Purpose of the Study:

• To review current methods for assessing MRD in AML.
• To discuss the prognostic value of MRD detection.
• To advocate for the standardization of MRD assessment in clinical practice.

Main Methods:

• Review of various MRD assessment techniques, focusing on multiparameter flow cytometry (MPFC) and molecular methods (real-time quantitative PCR).
• Summarization of studies demonstrating the prognostic significance of MRD in pediatric and adult AML patients.
• Analysis of the advantages and disadvantages of MPFC and molecular MRD.

Main Results:

• MRD detection provides stronger prognostic information than morphological CR in AML.
• Both MPFC and molecular MRD methods are valuable for assessing residual disease.
• MRD levels correlate with treatment outcomes and resistance mechanisms.

Conclusions:

• MRD assessment is a more precise indicator of disease burden than morphological CR in AML.
• Standardizing MRD assessment (flow cytometry and molecular techniques) is crucial for clinical trials and individual risk stratification.
• MRD has the potential to serve as a surrogate endpoint for survival, facilitating faster drug approvals in AML.